1. New Concepts in Pain Management Melanie Christina, M.D. Presbyterian Hospital Dallas Medical Director, Heartland Hospice

2. INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN Definition : Pain n An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage n Pain is subjective. There is no neurophysiological or chemical test that can measure pain.

3. Prevalence of Pain n Over 30 million Americans suffer from chronic nonmalignant pain n 20-30% of the American public suffer from acute or chronic pain n Over 70% of patients with advanced cancer report having moderate to severe pain

4. Barriers in the treatment of Pain n Inadequate assessment n Specific populations more likely not to be treated n Patient’s reluctance to report pain n Patient’s reluctance to take opioids n Doctor’s reluctance to prescribe opioids –Fear of regulatory scrutiny –Fear of causing addiction –Lack of knowledge regarding dosing and side effects

5. Important concepts to Understand n Addiction –Psychological dependence on substances for their psychic effects and is characterized by compulsive use despite harm. n Analgesic Tolerance –The need to increase the dose of opioid to achieve the same level of analgesia. n Physical Dependence –A physiologic state of neuroadaptation which is characterized by the emergence of a withdrawal syndrome if drug use is stopped or decreased abruptly, or if an antagonist is administered. n Pseudoaddiction –Pattern of drug-seeking behavior of pain patients who are receiving inadequate pain medication. Behavior is mistaken for addiction.

6. Guidelines for the management and treatment of Pain n WHO - global initiative on pain management (1986) n Texas State Board of Medical Examiners (1993) n Federation of State Boards (1998) n JCAHO (1999) n Governmental guidelines (AHCPR) n American Pain Society n and many more!!!!!!

7. Texas State Board of Medical Examiners’ Position n “ Quality medical practice dictates that those citizens of TX who suffer pain and other distressing symptoms should be adequately relieved so that their quality of life is as optimum as can be.” n “The TSBME recognizes that opioids and other Scheduled Controlled substances, are indispensable for the treatment of pain…” n “It is the position of the board that these drugs be prescribed for the treatment of these symptoms in appropriate and adequate doses…”

8. Texas State Board of Medical Examiners’ Position n “ The Board recognizes that pain, and many other symptoms are subjective complaints and appropriateness and adequacy of drug and dose will vary from individual to individual.” n “The standard will be determined largely by treatment outcome…” n Physicians should be diligent in preventing (controlled substances) from being diverted from legitimate to illegitimate use.

9. Standards used by Board when evaluating use of Controlled substances: n DOCUMENTATION- Medical records should include: –medical history and physical –diagnostic, therapeutic and laboratory results –evaluations and consultations –treatment objectives –discussion of risks and benefits –treatments –medication (date, type, dosage, quantity) –instructions and agreements –periodic review

10. Joint Commission Standards on Pain Management n Patient’s have a right to appropriate assessment and management of pain n Pain needs to be assessed, documented and followed for appropriate interventions n Policies and procedures should support the appropriate use of pain medications n Patients and their families should be educated on pain management n Discharge planning should include symptom management

11. Governmental Guidelines www.guidelines.gov n 1995 - “Clinical practice guidelines for chronic non-malignant pain syndrome” n 1998 - “The management of persistent pain in older persons” n 1999 - “Procedure guideline for bone treatment pain” n 2000 - “Control of pain in patients with cancer. A national clinical guideline” n 2002 - “Clinical practice guideline for the diagnosis, treatment and management of reflex sympathetic dystrophy/complex regional pain syndrome”

12. Current Legal Climate - Undertreatment of Pain Landmark case in California with a family suing the doctor for inadequate pain control in their dying, 85 year old father during the last week of his life. Jury trial awarded family 1.5 million claiming the physicians lack of attention to pain was “reckless negligence” and constituted elder abuse.

13. Tips for Physicians to protect themselves from charges of Undertreatment of pain: n Review your practice against JCAHO standards n Improve knowledge in pain assessment and treatment n Utilize local consultation resources n Improve knowledge and skills in assessing substance abuse; utilize local resources for substance abuse referrals and treatment

14. TYPES OF PAIN Pathophysiologic categorization n NOCICEPTIVE –SOMATIC n Stimulation of the somatic nervous system n skin, soft tissue, muscle, bone n easily localized –VISCERAL n stimulation of the autonomic nervous system n GI and GU tracts, cardiac, lung n difficult to describe and localize n NEUROPATHIC –PERIPHERAL PROCESSES (neuroma) –CNS PROCESSES (phantom pain) –COMPLEX REGIONAL PAIN

15. Classification of Pain Based on clinical course n Acute pain n Chronic pain (non-cancer) n Cancer pain n Post-surgical pain

16. AHCPR 1994 Assessment of Pain “ABCDE” Mnemonic n Ask about pain regularly; Assess pain systematically n Believe the patient and family in their reports of pain and what relieves it n Choose pain control options appropriate for the patient, family and setting n Deliver interventions in a timely, logical and coordinated fashion n Empower patients and their families; Enable them to control their course to the greatest extent possible

17. Describing Pain: “PQRST” Mnemonic n Provoking or Palliative factors n Quality of pain n Radiation n Severity n Temporal

18. Goals in the treatment of pain n Improve quality of life n Encourage mobility n Reduce hospitalizations and ER admissions n Improve job performance n Impact function in a family unit n Prevent depression/suicide

19. Aspirin Acetaminophen Nonsteroidal anti-inflammatory drugs + Adjuvants Morphine Hydromorphone Methadone Fentanyl Oxycodone + Nonopioid analgesics + Adjuvants Step 1, Mild Pain Step 2, Moderate Pain Combination opioids Tramadol + Adjuvants Step 3, Severe Pain WHO 3-STEP LADDER

20. Utilization of Opioids: Chronic Pain n Dose around the clock - achieve blood levels in the therapeutic range and avoid blood levels falling below pain threshold n Rescue dosing - 10% of total 24 hour dose n Dose titration: –mild pain: increase dose by 10% –moderate pain: increase dose by 25-50% –severe pain: increase dose by 100%

21. Routes of Administration n Oral - preferred n Buccal/sublingual n Rectal n Transdermal n Subcutaneous n Intravenous n Intramuscular - CONTRAINDICATED n Intrathecal

22. Equianalgesic Conversion Table

23. Variables in Considering Equianalgesic Doses n Pain intensity n Prior opioid exposure n Incomplete cross tolerance n Age of Patient n Route of administration n Level of Consciousness n Preexisting conditions

24. Common Side Effects and treatments n Constipation - All patients on opioids need a regular bowel program. n Nausea - quickly develop tolerance to this n Pruritus - may need to switch opioids n Sedation - if tolerance doesn’t occur can use stimulants n Respiratory depression - most feared yet rare side effect if proper dosing followed

25. Fear of Respiratory Depression from Opioid Use n Patients develop tolerance to the respiratory depressant effects early in course of therapy n Patients with COPD have been shown to experience improvement in exercise tolerance and decreased SOB n Terminally ill patients required 1.5-2.5 times their regular dose of analgesia to control breathlessness; without effect on O2 saturation or respiratory rate Annals Internal Medicine 119: 906, 1993

26. Fentanyl Transdermal System n Medication is absorbed into the subcutaneous tissue; then absorbed into systemic circulation via capillaries n May take 18-24 hours before effect of medication therefore not idea for acute pain management n Continue previous medicine for 18-24hr after placing the patch n Use short-acting opioid for rescue dosing n Adjust dose no sooner than every 6 days n Once removing patch the effect may persist for up to 24 hours

27. GOOD RULE OF THUMB: 2 X DURAGESIC DOSE = 24 HOUR MORPHINE DOSE Duragesic: Oral Morphine Equianalgesic Table

28. Steps in Changing Opioids n Calculate 24 hour dose of current opioids n Use equianalgesic table - convert dose of current drugs to equivalent new drug n Adjust the dose of new drug to accommodate patient variability and incomplete cross tolerance n Determine dosing intervals according to duration of action of new opioid n Calculate rescue dose

29. Example: Mr. Kaye is receiving 8mg Dilaudid po q 3h, and his physician would like to change the patient to a sustained release morphine product for patient convenience. n Calculate the 24 hour dose of Dilaudid –8mg x 8 = 64mg Dilaudid n Using the morphine:Dilaudid ratio figure the 24 hour equianalgesic dose morphine –Morphine: Dilaudid (4:1) –Multiply 64 by 4 = 256mg morphine equivalent n Divide the 24 hour dose by 12 for the long-acting morphine dose –256 divided by 2 = 128 or rounded up to MS Contin 130mg q 12hour

30. On the same patient, figure what the rescue dose of short-acting morphine would be? n Figure the total 24 hour dose of routine medication being given –260mg morphine per day n 10% of that can be given every 1-2 hours as needed for breakthrough pain –10% of 260 = 26mg –can give morphine immediate release tablets (30mg) q 1-2 h or morphine liquid (20mg/ml) 1.25 ml q 1-2 hour

31. On the same patient, if he were to stop swallowing what could be done? n Switch to IV therapy –Figure the total dose of morphine given (260mg) –Use the equianalgesic chart to figure oral:parenteral ratio (3:1) –Divide 260mg by 3 = 87mg IV morphine/day –Decide the route (subcutaneous or IV) –Divide 87mg/24hour = 3.6mg/hour –Have boluses of 25-50% total hourly dose available q 15-30mins (1-2mg) n Use MS Contin rectally at the same dose and give the rescue dose as a sublingual medication n Use sublingual medication on a q 4 hour schedule

32. On the same patient, if Mr. Kaye stopped swallowing tablets but had an extended prognosis? n Consider switching to Duragesic Patch –Total Morphine dose 260mg –Duragesic patch dose (per table) is 75ug/h –Via 2x rule: 260/2=130 or 125ug/h –Same breakthrough medication is appropriate n Stop the previous routine medication 18-24 hours after the patch is placed

33. Bone Pain from Metastasis n NSAID n Steroids n Bisphosphonates n Radiopharmaceuticals n Radiation Therapy

34. Neuropathic pain n Definition: Arising directly from central and peripheral damage by injury, disease or medical treatment. A pathological pain that serves no adaptive purpose. n Frequently becomes chronic and may escalate over time n Challenging to diagnose and treat

35. NOCICEPTORS react to noxious stimuli (heat, chemical, mechanical) A-delta fibers C fibers Nociceptors terminate in the DORSAL HORN and synapse in the Rexed Laminae SPINOTHALAMIC TRACTS send transmission rostrally after decussating in spinal cord Nociceptive signals ascend in the ANTEROLATERAL WHITE MATTER Termination in THALAMUS with afferent fibers projecting rostrally to the somatosensory CORTEX and LIMBIC SYSTEM Afferent Pain Pathways

36. Mechanism and Mediators of Pain n Painful stimuli causes depolarization of A-DELTA (thinly myelinated) and C-FIBER (unmyelinated) n Inflammation from chemical messengers released from damaged tissue (AMP, Protein), mast cells (Prostaglandin), macrophages (cytokines) n This leads to lowering of activation threshold and ectopic discharges = Peripheral sensitization n Neuron itself releases substance P which turns on messengers of immune cells n Positive feedback loop n Increase input into Dorsal Horn

37. Peripheral Sensitization n Lowering of the nociceptor depolarization threshold and increase in ectopic discharges n Due to altered expression and distribution of sodium channels at the level of injured nociceptor and Dorsal Root Ganglion

38. Mechanisms of Pain in the Dorsal Horn n Depolarized Nociceptors release Glutamate at the terminal end n Glutamate normally binds to AMPA receptor causing depolarization of DH cells n With peripheral sensitization and increase input, the NMDA receptor becomes exposed and Glutamate binds NMDA and AMPA. (wind-up) n This sensitizes central nervous system such that subthreshold input depolarize neurons

39. Central Sensitization n Lowering of the threshold of spinal horn neurons, with an increase magnitude and duration of response to stimulation n Expansion in size of receptive field n Release of tachykinins (substance P and neurokinin A) –These bind to neurokinin receptor and increase intracellular calcium –Increases NMDA receptor up regulation –Increase in Nitrous oxide synthetase

40. Importance of NMDA Receptor n The NMDA Receptor is involved in the propagation of neuropathic pain n Tolerance is also related to this receptor n When the NMDA Receptor is activated, there is Central Sensitization n The opioid receptor, mu receptor, is less responsive to opioids

41. NEUROPATHIC PAIN Medical Management Surgical Management Decompression Nerve Blocks Local Anesthetics Membrane stabilizing Agents Drugs that enhance dorsal horn inhibition NMDA Receptor Antagonist STEROIDS ANTIARRHYTHMICS Lidocaine Mexilitine ANTIEPILEPTICS Carbamazepine Oxcarbazepine Phenytoin Valproate Ketamine Dextromethoraphan Methadone Amantadine GABA-B agonists Baclofen ANTIDEPRESSANTS Amitriptyline Desipramine Imipramine Nortriptyline ANTIEPILEPTICS Oxcarbazepine Clonazepam Gabapentin

42. Most commonly used adjunctive treatments n Amitryptilline n Carbamazepine n Gabapentin n Corticosteroids

43. Methadone n A Mu agonist and noncompetitive NMDA receptor antagonist n No neuroactive metabolites n Elimination is independent of renal function n Less constipating n Good oral bioavailability n Extremely low cost

44. Conversion to Methadone

45. Interesting Case: 65yr old Anesthesiologist with Diabetic Peripheral neuropathy n Mr. C. has stocking-glove distribution neuropathy. He had excruciating pain (10/10) while on Norco (10/325mg) 6-8 per day. n Neurontin was not well tolerated n Elavil was contraindicated due to cardiac history and conduction system disorder n Mr. C. was depressed and didn’t think life was worth living with this pain

46. Neuropathic pain due to Diabetes n After discussion with patient and family, we initiated a course of Methadone n His current dose of Hydrocodone was 60-80mg daily or the equivalent of 60- 80mg morphine n My conversion with Methadone at low dose morphine is 5:1 n I started Mr. C on Methadone 5 mg q 8 ATC with 2.5mg q 3 hours prn

47. Methadone for neuropathic pain n Patient tolerated Methadone well n Within 24 hours his 10/10 pain was rated at 3/10 n Within 1 week, his pain was gone (0/10); n Precaution using Methadone: Slow accumulation, varied half-life, needs to be adjusted upward slowly (about q 7 days)